Skip to main content
GALT
NASDAQ Life Sciences

Galectin Narrows Q3 Loss to $3.6M as Phase 3 Protocol Sits With FDA

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.1
Mkt Cap
$307.591M
52W Low
$2.025
52W High
$7.13
52W Position info
53% above low
Off High info
57% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GALT sits 53% above its 52-week low of $2.025.

Summary

Galectin posted a Q3 net loss of $3.6 million, or $0.04 a share, versus $8.2 million, or $0.13 a share a year ago — the improvement driven mainly by lower interest expense and a $594 thousand derivative gain rather than operations. Cash stood at $11.7 million on September 30, with $10 million still available on the chairman's line of credit, which management says funds operations through June 2027. The 10-Q filed today carries a going-concern flag, so the runway statement is the number that matters most here. On the pipeline, the registrational Phase 3 protocol for belapectin in MASH cirrhosis with portal hypertension went to the FDA in Q3 after alignment on the composite liver outcome endpoint, blinded central variceal review, and a single 2 mg/kg LBM dose. New AASLD data showed a 15.9% placebo-adjusted improvement (p=0.04) in ANTICIPATE-NASH predicted CSPH risk at 18 months. Additional Phase 3 detail is expected at the December 3, 2026 annual stockholders' meeting, where shareholders also vote on a 100 million share authorized-increase proposal.

At the time of this announcement, GALT was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $307.6M. The 52-week trading range was $2.03 to $7.13. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Nov 16, 2026, 7:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $3.10 info
Change: -$0.0050 (-0.16%) info
Market Cap: $312.13M info
GALT
Oct 13, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $3.10 info
Change: -$0.845 (-21%) info
Market Cap: $312.13M info
GALT
Oct 02, 2026, 3:53 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $3.10 info
Change: -$0.820 (-21%) info
Market Cap: $312.13M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.10 info
Change: -$0.355 (-10%) info
Market Cap: $312.13M info
GALT
Aug 14, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.49
Real-time Price: $3.10 info
Change: -$0.395 (-11%) info
Market Cap: $312.13M info